Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Xcel Energy Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Xcel Energy Inc trades at $75.55 (market cap $46.62B). The key difference: Xcel Energy Inc is far larger — about 6.2× Spyre Therapeutics Inc. Common Stock's market cap, and Xcel Energy Inc pays a 3.18% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Xcel Energy Inc for 61 Days on average.
| SYRE | XEL | |
|---|---|---|
Market Cap | $7.52B | $46.62B |
Volume | 1,441,031 | 4,168,668 |
Sector | Health | Utilities |
52-Week High | $108.92 | $83.91 |
52-Week Low | $22.18 | $69.39 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $6.52B | $84.94B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Xcel Energy (XEL) trades at $75.36, up 1.6% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results with a Q2 2026 beat (EPS $0.93 vs. $0.79 expected) but a Q4 2025 miss. Revenue for 2025 was $14.67B with a net income margin of 15.28%, while the company maintains a P/E of 20.45 and ROE of 9.92%. News highlights include partnerships for electric school buses and growth from data center power demand.
The outlook is positive, supported by a $60 billion capital expenditure plan and rising power demand, offering potential upside to the $90.58 consensus price target. Key risks include wildfire liabilities, high debt levels, and regulatory scrutiny. The stock presents a balanced opportunity for income and growth investors, with a dividend yield around 3.3% and institutional accumulation noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
